Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13441355 | 1.00 | CYP1A2 (0.51) | CYP1A2CYP3A4CYP2C9HPGDOPRM1 | |
| SCHEMBL3576989 | 1.00 | CYP1A2 (0.51) | CYP1A2CYP3A4CYP2C9HPGDOPRM1 | |
| SCHEMBL13441335 | 0.94 | — | — | |
| SCHEMBL3578381 | 0.94 | — | — | |
| SCHEMBL3578382 | 0.94 | — | — | |
| SCHEMBL13441354 | 0.93 | OPRD1 (0.48) | OPRD1 | |
| SCHEMBL3579068 | 0.93 | OPRD1 (0.48) | OPRD1 | |
| SCHEMBL3579067 | 0.93 | OPRD1 (0.48) | OPRD1 | |
| SCHEMBL13441339 | 0.88 | OPRD1 (0.49) | OPRD1 | |
| SCHEMBL3576184 | 0.88 | OPRD1 (0.49) | OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683168-B2 | Compositions of novel opioid compounds and method of use thereof | Mount Cook Bio Sciences, Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| EP-1874315-A2 | COMPOSITIONS OF NOVEL OPIOID COMPOUNDS AND METHOD OF USE THEREOF | Mount Cook Biosciences, Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20070043028-A1 | Compositions of novel opioid compounds and method of use thereof | DMK PHARMACEUTICALS CORPORATION | 2007-02-22 | — | — | US | disclosed |
| WO-2006113468-A2 | COMPOSITIONS OF NOVEL OPIOID COMPOUNDS AND METHOD OF USE THEREOF | MOUNT COOK BIOSCIENCES, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043028-A1 | Compositions of novel opioid compounds and method of use thereof | OPRL1, OPRD1, OPRK1 | CYP1A2 1819/4885CYP3A4 2559/4885CYP2C9 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.